SNY - Sanofi

NYSE - Nasdaq Real Time Price. Currency in USD
38.87
-0.01 (-0.03%)
As of 10:56AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close38.88
Open39.01
Bid38.83 x 1300
Ask38.84 x 1200
Day's Range38.79 - 39.04
52 Week Range37.43 - 40.51
Volume274,637
Avg. Volume1,177,094
Market Cap96.827B
Beta0.83
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.86 (4.64%)
Ex-Dividend Date2018-05-09
1y Target EstN/A
Trade prices are not sourced from all markets
  • Motley Fool4 hours ago

    Is This European Drug Stock Giant a Buy?

    Here's an international healthcare stock to consider for your portfolio.

  • Moody's3 days ago

    AI Sirona (Luxembourg) Acquisition S.a.r.l. -- Moody's assigns Al Sirona Acquisition (Zentiva) a first-time rating of B3; outlook stable

    Moody's Investors Service, ("Moody's") has today assigned a first-time B3 corporate family rating (CFR) and a B3-PD Probability of Default Rating (PDR) to Al Sirona (Luxembourg) Acquisition S.a.r.l. ...

  • Motley Fool4 days ago

    Don’t Ignore European Healthcare Stocks

    International healthcare stocks could be a great fit for your portfolio.

  • 5 Companies To Watch As Marijuana Legalization Approaches
    Oilprice.com5 days ago

    5 Companies To Watch As Marijuana Legalization Approaches

    Canada is about to become the first major industrialized nation to legalize marijuana use across the country, and the companies that have positioned themselves to profit could see remarkable gains

  • TheStreet.com5 days ago

    Trump Administration Rolls Out Shaming as Drug Pricing Tool

    President Trump took heat for being too soft on drug companies in a speech last week. The Centers for Medicare and Medicaid Services on Tuesday, May 15, rolled out revamped Drug Spending Dashboards that likely will put pressure on drug companies to lower prices. The newly designed dashboards show how much is spent in Medicare Part B, Medicare Part D and Medicaid for name-brand drugs.

  • Sanofi Eczema Drug Dupixent Succeeds in Adolescents Study
    Zacks5 days ago

    Sanofi Eczema Drug Dupixent Succeeds in Adolescents Study

    Sanofi (SNY) announces positive results from a phase III study evaluating Dupixent for the treatment of moderate-to-severe atopic dermatitis in adolescents.

  • AstraZeneca’s 1Q18 Estimates: CVMD Products
    Market Realist5 days ago

    AstraZeneca’s 1Q18 Estimates: CVMD Products

    AstraZeneca’s (AZN) Cardiovascular and Metabolic Disease (or CVMD) segment includes various products such as Brilinta, Farxiga, Bydureon, Byetta, Onglyza, and Symlin and legacy products such as Atacand, Crestor, and Seloken.

  • Bloomberg5 days ago

    Luxury Stocks Are Reshaping France's CAC 40

    A year ago LVMH, the owner of luxury brand Louis Vuitton, became France’s biggest company by market value, a mantle energy giant Total SA and drugmaker Sanofi SA had shared for almost a decade. Kering SA was nowhere in sight. A more than 200 percent rally since the start of 2016, and more than 70 percent over the past 12 months, has now put the owner of “it bag” brands within shouting distance of the top five stocks in the CAC 40 Index.

  • Layoffs hit Framingham corporate giants Staples, TJX, Genzyme
    American City Business Journals6 days ago

    Layoffs hit Framingham corporate giants Staples, TJX, Genzyme

    Genzyme recently cut 95 jobs in Framingham, while TJX and Staples, both headquartered in the city, have slashed a combined 477 workers in undisclosed locations.

  • The Likely 5 Winners Of Canada’s Cannabis Boom
    Oilprice.com7 days ago

    The Likely 5 Winners Of Canada’s Cannabis Boom

    The marijuana market in North America is growing at an astounding rate, with investors who are in the know set to reap most of the rewards

  • Is Sanofi’s (NYSE:SNY) Balance Sheet Strong Enough To Weather A Storm?
    Simply Wall St.7 days ago

    Is Sanofi’s (NYSE:SNY) Balance Sheet Strong Enough To Weather A Storm?

    Investors pursuing a solid, dependable stock investment can often be led to Sanofi (NYSE:SNY), a large-cap worth US$94.36B. Doing business globally, large caps tend to have diversified revenue streams andRead More...

  • Merck and AstraZeneca Announced EMA Approval for Lynparza
    Market Realist13 days ago

    Merck and AstraZeneca Announced EMA Approval for Lynparza

    Lynparza (olaparib) is a poly(ADP-ribose) polymerase inhibitor, or PARP inhibitor, and part of Merck & Co. (MRK) and AstraZeneca’s (AZN) global strategic oncology collaboration.

  • Investopedia13 days ago

    Warren Buffett's 10 Big Stock Losers

    Warren Buffett is widely recognized as the greatest investor in the world, based on a decades-long record of outperformance, but he's the first to acknowledge that he's merely mortal, with more than his share of mistakes. The Oracle of Omaha announced in 2018 that Berkshire Hathaway completely exited its IBM position.

  • How Repatha Is Positioned after 1Q18
    Market Realist13 days ago

    How Repatha Is Positioned after 1Q18

    In 1Q18, Amgen’s (AMGN) Repatha revenue grew 15% YoY (year-over-year) to $123 million from $49 million, primarily due to higher unit demand. It grew ~26% quarter-over-quarter. In US and international markets, Repatha generated revenue of $84 million and $39 million, respectively, compared with $33 million and $16 million in 1Q17.

  • Alimta: An Emerging Drug to Treat Lung Cancer
    Market Realist14 days ago

    Alimta: An Emerging Drug to Treat Lung Cancer

    On April 30, the FDA granted priority review status to the sBLA (supplemental biologics license application) seeking approval for the combination of Merck’s (MRK) Keytruda, Eli Lilly’s (LLY) Alimta, and platinum-based chemotherapy agents like carboplatin or cisplatin in first-line metastatic NSCLC (non-squamous non-small cell lung cancer) indication. The Prescription Drug User Fee Act’s date is September 23. The sBLA is based on data from the Phase 3 KEYNOTE-189 trial declared on April 16. ...

  • How Amgen’s Nplate, Vectibix, and Neupogen Performed in 1Q18
    Market Realist14 days ago

    How Amgen’s Nplate, Vectibix, and Neupogen Performed in 1Q18

    In 1Q18, Amgen’s (AMGN) Nplate revenue grew 16% YoY (year-over-year) to $179 million from $154 million, primarily driven by unit demand. It grew ~8% QoQ (quarter-over-quarter).

  • With A -24.41% Earnings Drop, Is Sanofi’s (EPA:SAN) A Concern?
    Simply Wall St.14 days ago

    With A -24.41% Earnings Drop, Is Sanofi’s (EPA:SAN) A Concern?

    Measuring Sanofi’s (ENXTPA:SAN) track record of past performance is a valuable exercise for investors. It allows us to understand whether or not the company has met or exceed expectations, whichRead More...

  • 3 Reasons Regeneron Stock Could Start Climbing Again
    Motley Fool15 days ago

    3 Reasons Regeneron Stock Could Start Climbing Again

    It's been a rough few years, but things are looking up in more ways than one.

  • Are These Disappointing Drugs Back on Track to Billions?
    Motley Fool16 days ago

    Are These Disappointing Drugs Back on Track to Billions?

    Sales of these heart disease drugs have been lackluster so far, but that may not be the case for too much longer.

  • Alnylam's (ALNY) Q1 Loss Wider than Expected, Sales Miss
    Zacks17 days ago

    Alnylam's (ALNY) Q1 Loss Wider than Expected, Sales Miss

    Alnylam (ALNY) incurs narrower-than-expected loss and missed revenue estimates in Q1. With several pipeline related events lined up and potential approval for patisiran, we expect investor focus to remain on the related updates.

  • Regeneron Topples Despite Surprising Beat For Blockbuster Eye Drug
    Investor's Business Daily18 days ago

    Regeneron Topples Despite Surprising Beat For Blockbuster Eye Drug

    Regeneron reported better-than-expected adjusted earnings of $4.76 a share. The biotech's revenue of $1.51 billion came in a little below some forecasts.

  • Regeneron (REGN) Q1 Earnings Top, Sales Lag, Updates View
    Zacks18 days ago

    Regeneron (REGN) Q1 Earnings Top, Sales Lag, Updates View

    Regeneron's (REGN) first-quarter results were mixed as earnings beat expectations while sales missed the same. Nevertheless, Eylea sales were impressive.

  • InvestorPlace18 days ago

    Pfizer Inc. Is Stuck in a Trading Range – for Now

    Pfizer’s drug Viagra coming off patent protection is still the biggest headwind for PFE stock at the moment. PFE lost its exclusivity for Viagra in December and is the primary reason for the company reporting revenues dropping 2% operationally.

  • Esperion Therapeutics Dives — But Test Results 'Strong In This Context'
    Investor's Business Daily19 days ago

    Esperion Therapeutics Dives — But Test Results 'Strong In This Context'

    Esperion Therapeutics lost a third of its value Wednesday after its cholesterol drug underperformed bullish expectations in a late-stage study.

  • Comparing Analysts’ Views on Sanofi and GlaxoSmithKline
    Market Realist19 days ago

    Comparing Analysts’ Views on Sanofi and GlaxoSmithKline

    Sanofi’s (SNY) EV (enterprise value) is $107.7 billion, and its EV-to-revenue ratio is 2.4. The stock is trading at a forward PE (price-to-earnings) ratio of 11.2, and its price-to-earnings-to-growth ratio is 2.2. Sanofi’s price-to-sales ratio is 2.3, and its price-to-book ratio is 1.4. The company’s operating margin is 20.4%. Sanofi has generated an ROA (return on assets) of 4.5% and an ROE (return on equity) of 6.8%.